Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Mesothelioma |
| Start Date: | February 1, 2006 |
| Phase: | Phase II |
| Status: | Completed |
| NCT ID: | NCT00295503 |
| Study Type: | Interventional |
| Intervention: | Drug: bevacizumab|Drug: cisplatin|Drug: pemetrexed |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | University of Texas Southwestern Medical Center|University of Chicago|Columbia University |
| Ages: | Adult|Senior |
| Enrollment: | 55 |
| Funded By: | Other |
| First Received: | February 22, 2006 |
| End Date: | August 1, 2010 |
| Last Updated: | August 16, 2010 |
| Last Verified: | February 1, 2006 |